Review Course Virtual Office Hours - 2024

Michael H. Baumann, PhD, is a Staff Scientist and Facility Head at the National Institute on Drug Abuse (NIDA), Intramural Research Program (IRP), in Baltimore, MD. For more than 30 years, his research team has investigated the biological effects of therapeutic and abused drugs in preclinical laboratory models. Dr. Baumann has co-authored more than 200 scientific publications about his research findings and serves on the editorial board for several pharmacology journals. In 2012, he established the Designer Drug Research Unit (DDRU), the goal of which is to collect, analyze, and disseminate the most up-to-date information about the pharmacology and toxicology of newly emerging synthetic drugs of abuse, now known as new psychoactive substances (NPS). Working with partner organizations such as the Center for Forensic Science Research and Education (CFSRE), the Drug Enforcement Administration (DEA), and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Dr. Baumann is kept informed about trends in NPS misuse. His research team has characterized the molecular mechanism of action for many of the “bath salts” cathinones and “spice/K2” cannabinoids. Ongoing research is aimed at determining the biological effects of emerging synthetic stimulants, cannabinoids, and opioids which pose serious public health risks.

Ricardo Restrepo, MD, MPH finished his medical school in Medellín, Colombia. He then did his residency training in Psychiatry at Boston University Medical Center where he completed a fellowship in Addiction Psychiatry. He received an MPH in Global Public Health from NYU in 2008, while working at St Luke’s/Roosevelt Hospital, where he was Director of the Addiction Psychopharmacology Clinic at the Addiction Institute of New York. 

Since 2012, he works at the Long Beach VA Hospital, where he is the Medical Director of the SATP/Buprenorphine Clinic. Ricardo holds an academic position as Associate Clinical Professor of Psychiatry at the University of California (Irvine and Riverside) School of Medicine and most recently at the Charles Drew University, Los Angeles. He teaches and supervises students, psychiatry, family medicine and internal medicine residents. He serves as committee member of the American Academy of Addiction Medicine (AAAP) as well as on the California Society of Addiction Medicine (CSAM) Conference planning committee. 

 Ricardo's academic interests include the psychotherapy and psychopharmacology of addiction and the teaching of Psychiatry and Addiction Medicine. He is actively involved in issues related to transcultural psychiatry and behavioral addictions. He has worked with immigrant populations in the United States for over 20 years. As a volunteer for Physicians for Human Rights (PHR), he has participated in projects in the United States, Latin America and the Middle East. He has served as a United Nations Consultant since 2005. 

Dr. Restrepo has written chapters on addiction and human rights textbooks. He is the co-author of textbooks on buprenorphine as well as women’s health and addiction, and he cooperated with the Translation of DSM-5 to Spanish. He is board re-certified in Psychiatry and Addiction Psychiatry and a professional musician.

Lewis Nelson, MD, FACEP, FACMT, DFASAM is Professor and Chair of the Department of Emergency Medicine and Chief of the Division of Medical Toxicology at Rutgers New Jersey Medical School in Newark, NJ. He is a member of the Board of Directors of the American Board of Emergency Medicine and a Past-President of the American College of Medical Toxicology. He remains actively involved with the CDC, FDA, DHS, and several professional medical organizations, including ASAM. Dr. Nelson is an editor of the textbook Goldfrank’s Toxicologic Emergencies and on the editorial boards of several journal.

Michael Fingerhood, MD, FACP, DFASAM is an Associate Professor of Medicine and Public Health, and Chief of the Division of Addiction Medicine at Johns Hopkins Bayview Medical Center. He earned his Bachelor of Arts degree from The Johns Hopkins University and his Medical Degree from the Albert Einstein College of Medicine. He completed internal medicine training and a chief resident year at Johns Hopkins Bayview Medical Center. The mission of his career has been to promote and improve the provision of medical care to patients with substance use disorder, including the treatment of HIV and hepatitis C, with the development, maintenance and evaluation of innovative programs related to the care of these individuals. Dr. Fingerhood created the Comprehensive Care Practice in 1994, a primary care practice largely devoted to providing care to individuals with substance use disorder. The practice has been innovative in integrating buprenorphine treatment into the primary care setting for over 650 individuals. He has also co-created novel buprenorphine treatment programs at a community center, at a church and in a mobile van outside the Baltimore detention center. He is co-author of the ASAM Handbook of Addiction Medicine.

Carla Marienfeld, MD, is a board-certified addiction psychiatrist and Clinical Professor at the University of California, San Diego who supports recovery in an evidence based, harm-reduction approach through therapy, motivational interviewing, and medication treatment. Her research involves analysis of electronic medical record data for individuals with substance use disorders. She has authored or co-authored over 35 peer reviewed articles, book chapters, practice guidelines, and invited commentaries, and she edited two books: Motivational Interviewing for Clinical Practice and Absolute Addiction Psychiatry Review: An essential board exam study guide. She has been highly involved in education of colleagues and trainees about addiction psychiatry and effective interventions including buprenorphine treatment and motivational interviewing, and she is the fellowship director for the UCSD Addiction Psychiatry Fellowship. Dr. Marienfeld completed a fellowship in addiction psychiatry and residency training in psychiatry at Yale. During her residency, she was chief resident of psychiatry and founded (and later led) the Yale Global Mental Health Program. She earned a medical degree with honors from Baylor College of Medicine in Houston.

Annie Levesque, MD, MSc is the Medical Director of the Opioid Treatment Program at the Addiction Institute at Mount Sinai West. She is also the Associate Director of the Fellowship in Addiction Medicine Program at the Icahn School of Medicine at Mount Sinai. After receiving her medical degree from the University of Montreal, Dr. Levesque completed a Family Medicine and a Clinician-Scholar residency program at the University of Montreal, an Addiction Medicine fellowship at Mount Sinai West Hospital and a Masters in Experimental Medicine at McGill University

Dr. Leslie Hayes, MD, works for El Centro Family Health in Espanola, NM. She is board-certified in both addiction and family medicine. While Dr. Hayes enjoys all aspects of family medicine, her particular passion is taking care of people with opioid use disorder. She especially enjoys working with pregnant women and new mothers who have had drug problems and works hard to make sure that they and their babies receive compassionate and appropriate medical care. She got much of her training in substance use disorders through Project ECHO and now considers herself extremely fortunate to have been able to give back to Project ECHO, and she now provides training for other providers around the state of New Mexico and nationally in substance use disorder and use of buprenorphine. She recently started an ECHO in her own organization with the goal of getting 90% of providers trained to prescribe buprenorphine and provide compassionate, evidence-based care for Substance Use Disorder. She was named a White House Champion of Change in April of 2016 for her work with substance use disorder and pregnancy. Her work was also featured in The Providers, an award-winning documentary about rural health care.

Jonathan Avery, MD is currently the Director of Addiction Psychiatry and an Associate Professor of Clinical Psychiatry at Weill Cornell Medical College and New York-Presbyterian Hospital. In addition to his clinical work, Dr. Avery teaches addiction psychiatry to the Weill Cornell medical students and residents of New York-Presbyterian Hospital. He has been published on a broad variety of topics in psychiatry, including papers on subjects ranging from clinician attitudes towards patients to how to use buprenorphine. He is the founder of the Addiction Stigma Institute that studies stigma towards individuals with substance use disorders and creates novel interventions to improve these stigmatizing attitudes. He was on the editorial board for the DSM-5 Clinical Cases book and is the editor of the books Co-occurring Mental Illness and Substance Use Disorders: A Guide to Diagnosis and Treatment and The Stigma of Addiction: An Essential Guide. He has won numerous awards for his clinical and academic work, including the American Board of Psychiatry and Neurology Faculty Innovation in Education Award and the Outstanding Faculty Member Award from the New York County Psychiatric Society.

Dr. Michael Fingerhood is an Associate Professor of Medicine and Public Health at the Johns Hopkins University. He is the Chief of the Division of Chemical Dependence and medical director of the Comprehensive Care Practice (CCP) at Johns Hopkins Bayview Medical Center. The CCP integrates substance use disorder treatment with primary medical care, including care for HIV and hepatitis C.

Dr. Mason Turner is the Associate Chief Medical Officer for Behavioral Health for Intermountain Health based in Salt Lake City, UT and Denver, CO.
His leadership in mental health care focuses on the development and evolution of strategic innovations in behavioral health care delivery that enhance quality of care and clinical excellence and are guided by principles of equity and inclusion of the patient/consumer voice into all aspects of the behavioral health ecosystem.
Including integration initiatives which link mental health care and addiction medicine services with both primary and specialty medical care, as well as supporting innovative technological means of reaching patients for treatment of behavioral health conditions, he is also committed to enhancing access for behavioral health care services to all those who need it. Additionally, he has extensive experience in promoting employee health and well-being in a variety of corporate and healthcare sectors.
As a clinician, he specializes in addiction medicine, consult-liaison psychiatry and treatment of personality disorders. He has received extensive training in resiliency-and systems-based approaches for improving the mental health and well-being of refugees, asylum seekers and torture survivors.
Dr. Turner also served as a former Assistant Clinical Professor in Psychiatry at the University of California, San Francisco Medical School, where he taught medical students at all levels the practice of interviewing patients and clinical reasoning skills. He also served as adjunct faculty at the University of Hawaii John A. Burns School of Medicine.
Dr. Turner earned his AB degree in psychology from Dartmouth College in Hanover, NH, and completed his MD degree at the University of Texas, Southwestern Medical Center/ Parkland Hospital in Dallas, TX. He completed his residency in psychiatry at Harvard University Medical School through Massachusetts General Hospital and McLean Hospital, in Boston, MA, with additional training in psychotherapy at the Center for Psychoanalytic Studies at Massachusetts General Hospital and addiction psychiatry at McLean Hospital. He is board certified in Psychiatry and Addiction Medicine through the American Board of Preventive Medicine.

Dr. Kan graduated from Northwestern University Medical School. He finished his General Psychiatry Residency and Forensic Psychiatry Fellowship at the University of California, San Francisco (UCSF). He is Board-certified by the American Board of Psychiatry and Neurology in General and Forensic Psychiatry and he is Board-Certified by the American Board of Addiction Medicine in Addiction Medicine. He is a member of the faculty at the UCSF Department of Psychiatry.

Dr. Kan enjoys teaching, in addition to his direct work with patients. He has won multiple awards for teaching and clinical care delivery. Dr. Kan teaches and supervises psychiatrists-in-training in his role as a faculty member at UCSF. Throughout the year, he speaks at professional conferences on topics including treatment of addictive disorders.

Dr. Kan offers forensic consulting services to courts and attorneys in civil, criminal, and administrative matters. He has testified in multiple states, counties and federal court as an expert witness. He is a member of the American Academy of Psychiatry and the Law.

Dr. Kan works in private practice and is the Chief Medical Officer of Bright Heart Health. Bright Heart Health's mission is to provide high-quality addiction treatment via telemedicine to all.

Dr. Kan is an active member of the California Society of Addiction Medicine (CSAM). CSAM is a physician organization dedicated to improving the treatment of substance use disorders. Dr. Kan has planned conferences and spoken to many physician and non-physician groups. Dr. Kan is a Past President of CSAM. Dr. Kan is a Distinguished Fellow of the American Society of Addiction Medicine (D.F.A.S.A.M.).

Dr. Kan has testified numerous times before the California Assembly and Senate on addiction treatment. Dr. Kan has testified before Congress advocating for expanding access to addiction treatment.

Amutha Rajagopal, MD, is a board-certified internal medicine, infectious diseases and addiction medicine specialist. She is a part of UC San Diego Health's Owen Clinic, one of the nation's outstanding primary care centers for HIV positive individuals and consults in UC San Diego Health hospitals. Dr. Rajagopal also holds a master's degree in public health with an emphasis in epidemiology.

Soteri Polydorou, MD is a practicing physician with board certifications in Addiction Medicine and Internal Medicine.  His involvement in the field of substance use disorder (SUD) treatment and education include serving as Medical Director of Addiction Services for Northwell Health and Associate Professor at the Zucker School of Medicine at Hofstra/Northwell.  Northwell Health is a regional health system of over 20 hospitals and nearly 800 outpatient facilities.  Dr. Polydorou is a member of various governmental and professional committees tasked with supporting the delivery and organization of addiction treatment.  Dr. Polydorou’s interests include public policy initiatives to address substance use disorders, optimizing access to SUD services within health systems, and implementation of innovative opioid use disorder treatments within various healthcare clinical settings.

Michael Weaver, MD, DFASAM is a Professor in the Department of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addiction (CNRA) at the McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth). He received his M.D. degree from Northeast Ohio Medical University, and completed Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University (VCU) Health System, and he is Board-certified in Internal Medicine through the American Board of Internal Medicine and certified in Addiction Medicine through the American Board of Preventive Medicine. Dr. Weaver is the Sub-Board Chair for Addiction Medicine on the American Board of Preventive Medicine, and also serves as the Chair of the Examination Committee for certification in Addiction Medicine. He has been a member of ASAM for over 20 years and has been a member of the Publications Council and the Annual Conference Program Planning Committee. He is currently involved in patient care, medical education, and research. Dr. Weaver sees patients in the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston. 

He has extensive experience teaching about addiction to medical students, residents, and community professionals at all levels. He has been involved in multiple research projects, and currently is collaborating with other researchers in the CNRA on studies involving cocaine, methamphetamine, marijuana, and electronic cigarettes. Dr. Weaver has multiple publications in the field of addiction medicine, including the book "Addiction Treatment" published by Carlat Publishing in 2017.

Deborah Dupnik, CAE, CCSM-A has been the Director of the American Osteopathic Board of Family Physicians since 2022. She also manages the American Osteopathic Addiction Medicine Conjoint Committee and the Geriatric Medicine CAQ. Previously, she served as the Executive Director for the Nurses Organization of Veterans Affairs (NOVA), the Board of Ambulatory Surgery Centers (BASC) and was responsible for managing the certification programs for both the Certified Administrator Surgery Center (CASC) and Certified Ambulatory Infection Preventionist (CAIP). Prior to NOVA and BASC, she served as the Executive Director for the National Center for Homeopathy, Assistant Executive Director for the Society For Biomaterials, the American Society For Histocompatibility and Immunogenetics, and the American Society of Hand Therapists. Deborah also served as the Director of Certification and Customer Service for the Commission for Case Manager Certification.
Deborah obtained a Baccalaureate Degree in Microbiology from the University of New Hampshire. She is a Certified Association Executive (CAE) - American Society of Association Executives (ASAE) as well as a Certified Customer Service Manager – Advanced (CCSM-A) - Customer Service Institute of America (CSIA).